Medincell publishes its consolidated annual financial results
June 10, 2024
June 10, 2024
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
June 3, 2024
June 3, 2024
Update of the 2024 financial calendar
May 27, 2024
May 27, 2024
[Replay] Videoconference: Company’s Latest News, Outlook, and R&D Activities
May 15, 2024
May 15, 2024
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
May 14, 2024
May 14, 2024
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
May 8, 2024
May 8, 2024
[Replay] Videoconference • Collaboration with AbbVie (French)
April 17, 2024
April 17, 2024
Medincell enters into strategic co-development and licensing agreement with AbbVie to develop next-generation long-acting injectable therapies
April 16, 2024
April 16, 2024
[Replay] Medincell Presentation at the 23rd Annual Needham Virtual Healthcare Conference
